What is the difference between Cartalax and Palmitoyl Tripeptide-1?

Cartalax: Tetrapeptide bioregulator from cartilage tissue; stimulates chondrocyte proliferation and extracellular matrix synthesis; normalizes gene expression in cartilage cells Palmitoyl Tripeptide-1: Palmitoylated GHK fragment; stimulates collagen I, III, and IV synthesis via TGF-β pathway; increases fibronectin and hyaluronic acid production

Is Cartalax FDA approved?

Cartalax is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

Is Palmitoyl Tripeptide-1 FDA approved?

Palmitoyl Tripeptide-1 is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

How is Cartalax administered in research settings?

In research settings, Cartalax is typically administered via the subcutaneous or oral routes. PeptideBase does not provide dosing or administration instructions.

How is Palmitoyl Tripeptide-1 administered in research settings?

In research settings, Palmitoyl Tripeptide-1 is typically administered via the topical route. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›Cartalax vs Palmitoyl Tripeptide-1

Peptide Comparison

Cartalax vs Palmitoyl Tripeptide-1

Name: Cartalax vs Palmitoyl Tripeptide-1 — Per-mg Price Comparison
Creator: PeptideBase
License: https://peptidebase.io/terms

Both are Skin & Cosmetic peptides.

Cartalax

Ala-Glu-Asp-Arg

Skin & JointNot EvaluatedResearch Only

Half-life: Unknown

6 providers listed

Full Cartalax profile →

Palmitoyl Tripeptide-1

Pal-GHK

Skin & JointNot EvaluatedResearch Only

Half-life: N/A (topical)

4 providers listed

Full Palmitoyl Tripeptide-1 profile →

Bottom line

Cartalax is carried by more providers on PeptideBase (6 vs 4); otherwise the two are closely matched on the measures we track.

Quick Verdict

Cartalax

Evidence

Preclinical

Palmitoyl Tripeptide-1

Evidence

Preclinical

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	Palmitoyl Tripeptide-1
Oral administration option	Cartalax
More provider options (6 vs 4)	Cartalax

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

Cartalax

Palmitoyl Tripeptide-1

Mechanism Family

Skin & Cosmetic

Half-life

Unknown

N/A (topical)

FDA Status

not evaluated

Admin Routes

subcutaneous, oral

topical

Availability

Research Only

Providers

6 listed

4 listed

Avail. Notes

Russian joint/cartilage peptide bioregulator (Khavinson Institute). Not FDA-approved. Not on any FDA list. Research chemical in US.

Cosmetic peptide (Pal-GHK, palmitoyl tripeptide-1). Palmitate conjugate of GHK tripeptide. Not regulated as a drug by FDA. No NDA or IND. Cosmetic anti-aging ingredient only.

Research Evidence

Cartalax

PreclinicalIn vitro · 1 key study · most recent 2023

Palmitoyl Tripeptide-1

PreclinicalReview · 2 key studies · dated evidence base — most recent 2015

Research Citations

Cartalax

In vitro2023 · Advances in Gerontology

KE peptide regulates SIRT1, PARP1, PARP2 gene expression and protein synthesis in human mesenchymal stem cell…

Palmitoyl Tripeptide-1

Review2015 · BioMed Research International

GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration

In vitro2012 · Journal of Peptide Science

Stem cell recovering effect of copper-free GHK in skin

About Cartalax

Tetrapeptide bioregulator from cartilage tissue; stimulates chondrocyte proliferation and extracellular matrix synthesis; normalizes gene expression in cartilage cells

Research Areas

cartilage regenerationjoint repairchondrocyte function support

About Palmitoyl Tripeptide-1

Palmitoylated GHK fragment; stimulates collagen I, III, and IV synthesis via TGF-β pathway; increases fibronectin and hyaluronic acid production

Research Areas

collagen synthesisskin firmnessanti-agingwound healing

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

Cartalax

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

Palmitoyl Tripeptide-1

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

Price (per mg)

Cartalax

$2.75/mg

$2.06 – $3.00 range

12 vendors

View price index →Find providers →

Palmitoyl Tripeptide-1

Not enough vendor pricing yet.

Find Providers

Where to source these peptides

Providers offering

Cartalax

6 listed

Browse directory →

Providers offering

Palmitoyl Tripeptide-1

4 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Skin & Cosmetic Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated July 20, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). Cartalax vs Palmitoyl Tripeptide-1 — Per-mg Price Comparison. Retrieved July 22, 2026, from https://peptidebase.io/peptides/compare/cartalax/palmitoyl-tripeptide-1

https://peptidebase.io/peptides/compare/cartalax/palmitoyl-tripeptide-1 Methodology License Download JSON Download CSV